Hepatocellular carcinoma: pick the winner—tyrosine kinase inhibitor versus immuno-oncology agent–based combinations

AC Bejjani, RS Finn - Journal of Clinical Oncology, 2022 - ascopubs.org
The treatment landscape for advanced hepatocellular carcinoma has changed dramatically
over the past 4 years. We now have numerous options for patients in frontline, second-line …
被引用次数：32 相关文章

Hepatocellular Carcinoma: Pick the Winner—Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent–Based Combinations

AC Bejjani, RS Finn - Journal of Clinical Oncology, 2022 - ingentaconnect.com
The treatment landscape for advanced hepatocellular carcinoma has changed dramatically
over the past 4 years. We now have numerous options for patients in frontline, second-line …

Hepatocellular Carcinoma: Pick the Winner-Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent-Based Combinations

AC Bejjani, RS Finn - … journal of the American Society of …, 2022 - pubmed.ncbi.nlm.nih.gov
The treatment landscape for advanced hepatocellular carcinoma has changed dramatically
over the past 4 years. We now have numerous options for patients in frontline, second-line …

Hepatocellular Carcinoma: Pick the Winner-Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent-Based Combinations.

AC Bejjani, RS Finn - Journal of Clinical Oncology: Official Journal …, 2022 - europepmc.org
The treatment landscape for advanced hepatocellular carcinoma has changed dramatically
over the past 4 years. We now have numerous options for patients in frontline, second-line …

Hepatocellular Carcinoma: Pick the Winner—Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent–Based Combinations

AC Bejjani, RS Finn - Journal of Clinical Oncology, 2022 - cir.nii.ac.jp
抄録< jats: p> The treatment landscape for advanced hepatocellular carcinoma has changed
dramatically over the past 4 years. We now have numerous options for patients in frontline …